A ‘designer’ manganese-peptide antioxidant of the world’s toughest bacterium, combined with radiation, have shown to be successful in the development of a vaccine to counter Venezuelan Equine Encephalitis Virus (VEEV), a biothreat agent, and Chikungunya virus, a mosquito-borne illness causing severe outbreaks around the world, according to a study “Deinococcus Mn2+-Peptide Complex: A Novel Approach to Alphavirus Vaccine Development,” published online May 30 in the journal, Vaccine, published by Elsevier, http://www.sciencedirect.com/
Effective vaccines depend upon the human immune system recognizing a biological structure that is similar to that of a disease-causing organism. A manganese-peptide antioxidant complex of Deinococcus, developed by Uniformed Services University of the Health Sciences (USU) pathology professor Dr. Michael J. Daly and his team, has the remarkable property of protecting proteins from ionizing radiation damage but not protecting the genetic material (DNA or RNA) in viruses and bacteria. Using D. radiodurans, listed in the Guinness Book of World Records as “the world’s toughest bacterium” and which can withstand 3,000 times the levels of gamma radiation that human cells can, Daly found that a disease-causing organism (pathogen) can be exposed to gamma radiation in the presence of a Deinococcus Mn complex, and rendered non-replicative (killed) by overwhelming genetic damage, but still maintain the shape of key surface proteins needed to mount a highly protective immune response. This approach was successfully implemented on viruses for the first time by scientists in the USU lab of the late Dr. Radha K. Maheshwari to produce vaccines against VEEV and Chikungunya virus.
This approach offers a simple, rapid, cost effective and potentially universal inactivation strategy that can be applied to any pathogen requiring immediate attention, for example, Ebola and Zika viruses.
“Application of this methodology has the potential to revolutionize all future vaccine development” says Dr. Paridhi Gupta, a scientist in the Maheshwari laboratory, and the study’s co-lead author.
The Latest on: Vaccine development
- Global BCG Vaccine Market Breakdown, Development and New Opportunities & Forecasts | Merck, Sanofi Pasteur, Japan BCG Lab on May 20, 2019 at 9:46 pm
May 21, 2019 (WiredRelease via COMTEX) -- A Comprehensive research study manages by Market.us on “Global BCG Vaccine Industry 2019″is an extensive, professional analysis bringing research data which ... […]
- Global Hepatitis A Vaccine Market : Technological Advancements Expected to Boost Revenue Growth During 2019-2028 || GSK, Merck, Sanofi on May 20, 2019 at 4:42 pm
You Can Request Demo Version of Report Before Buying Here (Use Corporate email ID to Get Higher Priority):https://market.us/report/hepatitis-a-vaccine-market/request-sample/ The development plans and ... […]
- WuXi Biologics Signed Letter of Intent for Long-Term Vaccine Manufacturing Contract on May 20, 2019 at 4:39 pm
development and manufacturing, today announced that it has entered into a strategic partnership Letter of Intent (LOI) with a global vaccine leader, pursuant to which WuXi Vaccines will build a ... […]
- Merck Joins TRANSVAC2 Program to Advance Vaccine Development and Manufacturing on May 20, 2019 at 5:01 am
- TRANSVAC2, part of the EU's Horizon 2020 program, provides trainings to streamline vaccine manufacturing and development - Merck to offer its M Lab Collaboration Center in Molsheim, France for ... […]
- MilliporeSigma Joins TRANSVAC2 Program to Advance Vaccine Development and Manufacturing on May 20, 2019 at 5:00 am
"Involvement in this project is a natural extension to our longtime focus on accelerating vaccine development and manufacturing," said Udit Batra, CEO, MilliporeSigma. "Through the TRANSVAC2 ... […]
via Google News and Bing News